330 / 879
Conclusion: Demonstrated PROS for MDMs
1.
Decreases waiting time to treatment
for H&N, pancreas, anus-
rectal and gynecological cancers
2.
Improves diagnostic/therapeutic paths and ensure application of
guidelines: yes for prostate, breast and glioma
3.
Changes treatments attitude and rate of intervention:
yes for
lung, breast and prostate
4.
Garantees/facilitates timely access to physical/phycho-emotional
rehabilitation programs: yes for prostate and breast
5. Helps and improves management of disease recurrence and timely
access to support and palliative care
6.
Helps enrollement in innovative and experimental therapies: yes for
colo-rectal cancers, breast and prostate
7. Improves the education of professionals involved in patients care
8.
Increases patients satisfaction: yes for prostate and breast
9.
Improves survival:
yes for lung, oesophageal, ovarian and HR
prostate cancers
10. Guarantees a minor risk of law suits
FM Boyle et al: J Clin Oncol 2005, A Fleissig et al Lancet Oncol 2006, MA Sidhom et al
Lancet Oncol 2006, CS Sternberg et al BJU int 2007, LE Horvath et al Lancet Oncol
2010, J Walsh et al BMC Heakth Serv Res 2010, EM Kesson et al BMJ 2012